Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2B3-101 in breast cancer with leptomeningeal metastases
NCT01818713Phase 2Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2013
- Primary completion
- Oct 2014
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin glutathione pegylated liposomal in leptomeningeal metastases (LM), sponsored by Netherlands Cancer Institute. Primary endpoint: Safety and preliminary response using the LM response score at 1 year. Status: unknown.
02
Drugs
doxorubicin glutathione pegylated liposomal
03
Conditions
leptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT01818713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818713.